Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desmopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 6/20 | 0.85 |
| ▸ | AVPR2 known ✓ | P30518 | 4/20 | 0.85 |
| ▸ | AVPR1B known ✓ | P47901 | 4/20 | 0.85 |
| ▸ | OXTR | P30559 | 9/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.85 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmopressin SCHEMBL13575732 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL13775933 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL2687079 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL10053268 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL22510 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29317578 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| SCHEMBL23382246 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL15933169 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL21131126 | 1.00 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL204511 | 0.98 | OXTR (0.82) | OXTRAVPR1AAVPR2AVPR1BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3655036-B1 | COMPOSITIONS FOR TREATING STRESS-RELATED DISORDERS | HOFFMAN TECH LLC (US) | 2024-09-04 | — | — | EP | claimed |
| US-20240277624-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | NANEXA AB (SE) | 2024-08-22 | — | — | US | claimed |
| CN-111670051-B | Biomolecular conjugates and uses thereof | 亚飞（上海）生物医药科技有限公司 | 2024-06-25 | — | — | CN | claimed |
| EP-4351529-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | Nanexa AB (SE) | 2024-04-17 | — | — | EP | claimed |
| CN-117106716-A | Method for culturing cells and kit and device for use in the method | 朱诺治疗学有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-116875635-A | Method, reagent cartridge, reagent and device for transduction | 朱诺治疗学有限公司 | 2023-10-13 | — | — | CN | claimed |
| US-20230190952-A1 | CELL SURFACE CONJUGATES AND RELATED CELL COMPOSITIONS AND METHODS | JUNO THERAPEUTICS GMBH (DE) | 2023-06-22 | — | — | US | claimed |
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOG (CN) | 2023-05-25 | — | — | US | claimed |
| CN-108431210-B | Method for culturing cells and kit and device for use in the method | 朱诺治疗学有限公司 | 2023-05-23 | — | — | CN | claimed |
| WO-2022258985-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | NANEXA AB (SE) | 2022-12-15 | — | — | WO | claimed |
| US-11517627-B2 | Cell surface conjugates and related cell compositions and methods | JUNO THERAPEUTICS GMBH (DE) | 2022-12-06 | — | — | US | claimed |
| US-12564632-B2 | Conjugates of biomolecule and use thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2026-03-03 | — | — | US | disclosed |
| EP-4647493-A2 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF | Juno Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12409304-B2 | Drug delivery devices with drug-permeable component and methods | TARIS BIOMEDICAL LLC (US) | 2025-09-09 | — | — | US | disclosed |
| US-12403098-B2 | Pharmaceutical dosage form for application to mucous membranes and methods for producing same | ESOCAP AG (CH) | 2025-09-02 | — | — | US | disclosed |
| US-20190194257-A1 | VASOPRESSIN-2 RECEPTOR AGONISTS | FERRING B.V. (NL) | 2019-06-27 | — | — | US | disclosed |
| US-20170260229-A1 | REACTION PROCESS WITH MEMBRANE SEPARATION | VITO NV (BE) | 2017-09-14 | — | — | US | disclosed |
| WO-2016042066-A1 | REACTION PROCESS WITH MEMBRANE SEPARATION | VITO NV (BE) | 2016-03-24 | — | — | WO | disclosed |
| US-20080261951-A1 | Condensed azepines as vasopressin agonists | ASHWORTH DOREEN MARY | 2008-10-23 | — | — | US | disclosed |
| US-20080261951-A1 | Condensed azepines as vasopressin agonists | ASHWORTH DOREEN MARY | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260229-A1 | REACTION PROCESS WITH MEMBRANE SEPARATION | POR, MGAM, DCXR | AVPR1A 2694/4885AVPR2 2275/4885AVPR1B 2384/4885 |
| US-20190194257-A1 | VASOPRESSIN-2 RECEPTOR AGONISTS | AVPR2, AVPR1A, AVPR1B | AVPR1A 2/4885AVPR2 1/4885AVPR1B 3/4885 |
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | CD47, FCGR2A, CD40 | AVPR1A 4087/4885AVPR2 4589/4885AVPR1B 3941/4885 |
| US-20080261951-A1 | Condensed azepines as vasopressin agonists | AVPR2, AVPR1A, AVPR1B | AVPR1A 2/4885AVPR2 1/4885AVPR1B 3/4885 |
| US-12564632-B2 | Conjugates of biomolecule and use thereof | FCGR2A, FCGR3B, TNFRSF9 | AVPR1A 2648/4885AVPR2 3091/4885AVPR1B 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.